We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The product is the first commercial test for fully automated high-throughput systems that can identify and differentiate between SARS-CoV-2, influenza A and influenza B using a single sample, according to the company. Read More
The trial is the first investigational device exemption study in the U.S. for a fully resorbable device to treat blocked arteries below the knees. Read More
With the widespread use of ultrasound by many different types of clinicians during the pandemic, “education is more important than ever,” the company said. Read More
The repair system “expands meniscal repair options to around 600,000 European patients annually where the only previous option was removal,” the company said. Read More
T2 said that clinical studies of the test, which used both positive and negative patient samples, showed a sensitivity of 95 percent and a specificity of 100 percent. Read More